A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Phase 2
Completed
- Conditions
- Advanced Pancreatic Cancer
- Registration Number
- JPRN-jRCT2080224088
- Lead Sponsor
- Bristol-Myers Squibb K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Must have histological or cytological confirmed diagnosis of locally advanced or metastatic adenocarcinoma of the pancreas, which has progressed on or after one line of chemotherapy
ECOG Performance status 0-1
Adequate organ functions
Measurable disease
Exclusion Criteria
Suspected or known CNS metastasis
Participants with active, known, or suspected autoimmune disease
Uncontrolled or significant cardiovascular disease
Prior exposure to selected immune cell-modulating antibody regimens
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method